The Neoadjuvant Administration of PD-1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous-Cell Carcinoma

Table 1

Clinical characteristics of locally advanced ESCC patients.

Characteristics	Locally advanced ESCC patients (N = 25)
Age (years), mean ± SD	59.7 ± 7.8
Gender, no. (%)
Female	7 (28.0)
Male	18 (72.0)
Tumor location, no. (%)
Upper	1 (4.0)
Middle	19 (76.0)
Lower	5 (20.0)
Histological type, no. (%)
ESCC	25 (100.0)
cT stage, no. (%)
cT2	2 (8.0)
cT3	23 (92.0)
cN stage, no. (%)
cN1	16 (64.0)
cN2	7 (28.0)
cN3	2 (8.0)
cM, no. (%)
cM0	25 (100.0)
cTNM, no. (%)
III	23 (92.0)
IVA	2 (8.0)
PD-1 regimen, no. (%)
Camrelizumab	12 (48.0)
Sintilimab	8 (32.0)
Others	5 (20.0)
Chemotherapy regimen, no. (%)
Paclitaxel + cisplatin	11 (44.0)
Paclitaxel + carboplatin	14 (56.0)
RT dose, no. (%)
40 Gy/20 F	13 (52.0)
41.4 Gy/23 F	12 (48.0)
PD-L1 CPS, no. (%)
0	0 (0.0)
1–4	13 (52.0)
5–9	8 (32.0)
≥10	4 (16.0)

ESCC, esophageal squamous-cell carcinoma; SD, standard deviation; cT, clinical tumor; cN, clinical node; cM, clinical metastasis; cTNM, clinical tumor-node-metastasis; PD-1, programmed cell death protein 1; RT, radiotherapy; 40 Gy/20 F, 40.0 Gy in 20 fractions; 41.4 Gy/23 F, 41.4 Gy in 23 fractions; PD-L1 CPS, programmed death ligand 1 combined positive score.